Latest Levosalbutamol Stories

2010-03-10 15:00:00

FORT LEE, N.J., March 10 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review. "We are pleased that the lurasidone NDA has been accepted for...

2009-12-02 17:52:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Markets for Asthma and COPD Drugs http://www.reportlinker.com/p0166826/Global-Markets-for-Asthma-and-COPD-Drugs.html Provides an in-depth analysis of the global market for medications that treat asthma and chronic obstructive pulmonary disease Contains global market forecasts through 2014 for medications that treat asthma and chronic obstructive pulmonary...

2009-09-01 09:26:00

PITTSBURGH, Sept. 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity. This product, which is indicated for the treatment or prevention of bronchospasm in patients over 6 years old with reversible obstructive airway disease, is the first...

2008-12-11 07:00:00

FAIRFAX, Va., Dec. 11 /PRNewswire-USNewswire/ -- Nancy Sander, president and founder of Allergy & Asthma Network Mothers of Asthmatics (AANMA) today urged committee members to preserve patient access to all forms of 12-hour bronchodilators at a joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee of the Food and Drug Administration held in Rockville, MD. Sander also requested the committee use...

2008-10-24 06:00:24

Sepracor Inc. (Nasdaq: SEPR) today announced that the EMEA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending to grant a marketing authorization for LUNIVIA(R) brand eszopiclone in the European Union (EU) for the treatment of insomnia. The EU labeling provides for patients who require longer-term therapy to be treated for up to six months, with the usual course of therapy for typical patients being short-term. LUNIVIA is marketed in the U.S....

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.